TY - JOUR T1 - EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment JF - Anticancer Research JO - Anticancer Res SP - 6685 LP - 6697 DO - 10.21873/anticanres.14692 VL - 40 IS - 12 AU - ANNA SZUMERA-CIEĆKIEWICZ AU - JAN POLESZCZUK AU - EWA PASZKIEWICZ-KOZIK AU - GRZEGORZ RYMKIEWICZ AU - KAMIL SOKÓŁ AU - ANITA BORYSIUK AU - MARTYNA KOTARSKA AU - DARIA OWCZAREK AU - MONIKA KAWECKA AU - BEATA PYTLAK AU - JAN WALEWSKI AU - MONIKA PROCHOREC-SOBIESZEK Y1 - 2020/12/01 UR - http://ar.iiarjournals.org/content/40/12/6685.abstract N2 - Background/Aim: Follicular lymphoma (FL) relapse within 24 months of the first immunochemotherapy (POD24) indicates more precisely poor overall survival and high risk of death. The aim of the study was to assess the potential value of POD24 in FL and describe the enhancer of zeste homolog 2 (EZH2) expression profile, in correlation with clinical/histopathological/immunophenotypical characteristics. Materials and Methods: This retrospective single-center study included 75 patients with FL treated under watch and wait (W&W) and immunochemotherapy regimens. All cases were immunohistochemically assessed: assays were performed for EZH2, CD10, BCL6, BCL2, MUM1, MYC and p53. Results: POD24 was independent of clinical/histopathological/immunohistochemical features and separated patients with inferior outcomes. EZH2 high expression was observed in high/low grade and follicular/diffuse FL patterns. BCL2-negative (p=0.042) and MUM1 (p=0.039), MYC (p<0.001), p53 (p<0.001) - positive cases had significantly higher EZH2 expression. Conclusion: POD24 is currently the most useful tool for the identification of poor outlook patients. EZH2 is crucial in FL biology, but the value of its protein expression is limited as a prognostic factor. ER -